Clinical Trial Record

Return to Clinical Trials

Combined Exercise and Nutritional Intervention in GI Cancer Patients


2022-03-21


2024-06-28


2024-06-28


68

Study Overview

Combined Exercise and Nutritional Intervention in GI Cancer Patients

Although some studies have focused on the role of exercise on inflammation and cytokine expression in cancer patients undergoing treatment and survivors, to our knowledge none have investigated the effect of exercise during neoadjuvant treatment as a complementary therapy to 1) modulate inflammation which may have a positive influence on chemotherapy response and 2) preserve or improve skeletal muscle, thus preventing cancer cachexia. Furthermore, we believe that the neoadjuvant treatment period could be a window of opportunity to optimize patient's nutritional status before surgery, which until now has been under used. Bearing in mind that nutritional interventions may also influence IL-6, our hypothesis is that a Combined Exercise and Dietary Intervention (CEDI) may induce positive alterations in cytokine profile and increase NK cell infiltration of the tumor in gastric and pancreatic cancer patients submitted to neo-adjuvant therapy.

N/A

  • Pancreatic Cancer
  • Gastric Cancer
  • Diet
  • Exercise
  • BEHAVIORAL: Combined Exercise and Dietary Intervention (CEDI)
  • BEHAVIORAL: Standard Care
  • 213/18

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-06-13  

N/A  

2024-03-18  

2022-06-13  

N/A  

2024-03-19  

2022-06-15  

N/A  

2024-03  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Other


Allocation:
Randomized


Interventional Model:
Parallel


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Combined Exercise and Dietary Intervention

Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention

BEHAVIORAL: Combined Exercise and Dietary Intervention (CEDI)

  • The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exer
OTHER: Control

Standard Care

BEHAVIORAL: Standard Care

  • Standard Care
Primary Outcome MeasuresMeasure DescriptionTime Frame
Mean Change in interleukin 6 (IL6)IL6 circulating levels will be determined before and after combined exercise and dietary intervention (CEDI)8 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Change in Immune cell infiltration profile on tumor specimenPeri-tumoral cell distribution (NK cells, T cells) will be determined before and after combined exercise and dietary intervention (CEDI)8 weeks
Change in skeletal muscleSkeletal muscle using CT scan body composition analysis will be assessed before and after combined exercise and dietary intervention (CEDI)8 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Sónia Velho

Phone Number: +351914644141

Email: soniavelho0@gmail.com

Study Contact Backup

Name: Marilia Cravo

Phone Number: 919439192

Email: marilia.cravo@sapo.pt

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
40 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • gastric or pancreatic cancer stage II/III, eligible for neoadjuvant chemotherapy,
  • age higher than 40 years and lower than 80 years,
  • ECOG (Eastern Cooperative Oncology Group) functional status: 0-2,
  • sedentary/low physical activity level.

  • Exclusion Criteria:

  • life expectancy less than 12 months at inclusion,
  • chemotherapy regimen other than 5-Fluorouracil, Folinic acid, Oxaliplatin, Docetaxel (FLOT) for gastric and 5-Fluorouracil, Irinotecan and Oxaliplatin (FOLFIRINOX) or gemcitabine for pancreatic cancer,
  • metastatic disease,
  • chronic anti-inflammatory medication use,
  • known inflammatory condition (rheumatoid arthritis, ankylosing spondylitis or chronic active hepatitis)
  • cardiovascular, respiratory or musculoskeletal or joint problems that preclude moderate physical activity.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • STUDY_DIRECTOR: Marilia Cravo, Hospital da Luz

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available